AveXis, Inc.
http://avexis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AveXis, Inc.
Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
Biotech’s Cambrian Explosion
An increasing number of sophisticated tools are on offer to address new therapeutic challenges and remaining unmet needs.
The Next Big Thing In Gene Therapy Might Not Be Gene Therapy
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
The Next Big Thing In Gene Therapy Might Not Be Gene Therapy
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Company Information
- Other Names / Subsidiaries
-
- BioLife Cell Bank, Inc.